Xoma | XOMA - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
AbbVie USD 3.58B 316M 2026-03
Agenus USD 10.56M 13.04M 2025-12
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Ardelyx USD 75.92M 7.69M 2025-12
aTyr Pharma USD 82.26M 77.46M 2025-12
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Celldex Therapeutics USD 7.84M 1.21M 2025-12
Curis USD 1.34M 3.45M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Incyte USD 328.1M 62.31M 2026-03
MacroGenics USD 7.94M 1.96M 2025-12
Novartis USD 3.14B 296M 2026-03
Novartis USD 3.44B 132M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Prothena USD 7.65M 5.59M 2025-12
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Xoma USD 11M 2.54M 2024-06